As shown in Table 2, it was the same for the patients with any gender, stage II-IV, T2–3, N1–3, M0, surgery alone, 5-FU-based adjuvant, intestinal-type and diffuse-type, Her2-positive and -negative carcinomas (p < 0.05). The gene discussed is ERBB2; the disease is carcinoma.